Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3154 Target Snapshot

Neuromedin-K receptor · SINGLE PROTEIN · Rattus norvegicus

140Compounds
31Assays
1Approved Drugs
136.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P16177. Use UniProt P16177 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P16177 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Neuromedin-K receptor as ChEMBL target CHEMBL3154, mapped to UniProt P16177. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Neuromedin-K receptor
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL3154
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P16177
Neuromedin-K receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Neuromedin-K receptor is the right protein anchor across sources, using UniProt P16177 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNeuromedin-K receptor
UniProt AccessionP16177
Component TypeProtein
Sequence Length452 aa

Neuromedin-K receptor

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Neuromedin-K receptor, mapped to UniProt P16177. Sequence length is 452 aa.

Mapped IDP16177
Review nameNeuromedin-K receptor
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

1
Approved
3
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC5047.0
KI30.0
EC5033.0
KD26.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3734811 10.89 EC50 0.013 Preclinical
CHEMBL106124 10.64 EC50 0.023 Preclinical
CHEMBL305119 8.3 Ki 5.0 Preclinical
CHEMBL65468 8.26 Ki 5.5 Preclinical
CHEMBL437797 8.2 EC50 6.3 Preclinical
CHEMBL106124 7.96 IC50 11.0 Preclinical
CHEMBL3422009 7.9 Ki 12.59 Preclinical
CHEMBL3361404 7.72 EC50 19.0 Preclinical
CHEMBL3422018 7.7 Ki 19.95 Preclinical
CHEMBL45340 7.52 IC50 30.0 Preclinical
Distribution

pChEMBL Value Distribution

12
5.0
25
5.5
8
6.0
15
6.5
12
7.0
11
7.5
3
8.0
0
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEZOLINETANT
CHEMBL3608680
Approved 2023
Assay Landscape

Assay Landscape

31
Total Assays
53
Tested Compounds
2
Assay Types
Functional — 17 assays, 40 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 14 35 5.6
cell-based format 2 5 9.0
tissue-based format 1 0
Binding — 14 assays, 53 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 7 20 6.9
assay format 4 8 6.8
cell membrane format 1 0
cell-based format 1 4 7.1
subcellular format 1 21 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine